EPO published patent application EP3996111A1 (filed March 25, 2026) for methods of purifying radium-226 containing solutions, producing radium-226 targets, and generating actinium-225 (Ac-225) for cancer therapy. The applicant is Nihon Medi-Physics Co., Ltd. with inventors Honda Yoshio and Yano Shinya. The technology relates to nuclear medicine and targeted alpha therapy for treating cancers (A61P 35/00), involving purification processes (C01F 13/00, B01D 59/26) and electrodeposition methods (C25C 1/22, C25D 3/54). The patent is designated across 31 European member states including Germany, France, the UK, Italy, Spain, and the Netherlands.\n\nPatent publications are informational notices that grant intellectual property rights rather than impose compliance obligations. No action is required from regulated entities. Pharmaceutical companies developing Ac-225 based radiopharmaceuticals, nuclear medicine facilities, and medical isotope producers should review the patent claims to assess potential IP considerations for their therapeutic development programs. The patent does not create regulatory requirements but establishes proprietary protection for the purification and production methods.